Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Doramapimod HCl is the salt form of Doramapimod, a member of the N-pyrazole-N'-naphthly urea class of p38 MAPK inhibitors, which binds to the kinase with both slow association and dissociation rates. BIRB -796 has entered clinical trials for the treatment of autoimmune diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Doramapimod HCl is the salt form of Doramapimod, a member of the N-pyrazole-N'-naphthly urea class of p38MAPK inhibitors, which binds to the kinase with both slow association and dissociation rates. BIRB -796 has entered clinical trials for the treatment of autoimmune diseases. |
Molecular Weight | 564.13 |
Formula | C31H38ClN5O3 |
CAS No. | 1283526-53-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Doramapimod HCl 1283526-53-3 PR 934-423 FPL-12944AA PR-934-423 Remacemide inhibitor inhibit